Polydex Pharmaceuticals Management
Management criteria checks 2/4
Polydex Pharmaceuticals' CEO is George Usher, appointed in Jan 1993, has a tenure of 30.58 years. directly owns 8.01% of the company’s shares, worth $546.08K. The average tenure of the management team and the board of directors is 29.6 years and 30.6 years respectively.
Key information
George Usher
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 30.6yrs |
| CEO ownership | 8.0% |
| Management average tenure | 29.6yrs |
| Board average tenure | 30.6yrs |
Recent management updates
No updates
Recent updates
CEO
George Usher (64 yo)
30.6yrs
Tenure
US$268,700
Compensation
Mr. George G. Usher has been the Chief Executive Officer of Polydex Pharmaceuticals Ltd. since 1996 and its President since 1993. Mr. Usher serves as the President of Chemdex, Inc., a subsidiary of Polydex...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 30.6yrs | US$268.70k | 8.01% $ 546.1k | |
| COO, Treasurer & Secretary | 29.6yrs | US$105.00k | no data | |
| Chief Financial Officer | 4.7yrs | no data | no data |
29.6yrs
Average Tenure
64yo
Average Age
Experienced Management: POLX.F's management team is seasoned and experienced (29.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 35.6yrs | US$268.70k | 8.01% $ 546.1k | |
| Director | 40.6yrs | US$13.72k | no data | |
| Independent Director | 25.6yrs | US$13.72k | no data | |
| Director | 13.1yrs | no data | no data |
30.6yrs
Average Tenure
81.5yo
Average Age
Experienced Board: POLX.F's board of directors are seasoned and experienced ( 30.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/08/07 01:25 |
| End of Day Share Price | 2023/08/07 00:00 |
| Earnings | 2023/04/30 |
| Annual Earnings | 2023/01/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Polydex Pharmaceuticals Limited is covered by 0 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|